Literature DB >> 23809385

Elevated levels of leukotriene B4 and thromboxane B2 distinguish chest pain of cardiac and non cardiac origin.

Febi John1, S Kavitha, Seema Panicker, Tiny Nair, M Indira.   

Abstract

OBJECTIVE: Myocardial infarction (MI) is often preceded by severe chest pain. The use of inflammatory markers to distinguish between chest pain of cardiac and non cardiac origin are not well reported. The aim of the study was to distinguish the chest pain of non cardiac and cardiac origin by using reliable inflammatory markers.
METHODS: The present study enrolled 80 subjects including chest pain which lead to myocardial infarction (n=40), non-cardiac chest pain (CP) patients (n=20) and healthy volunteers (N) (n=20). Leukotriene B4 (LTB4) and thromboxane B2 (TXB2) levels were analyzed along with hs-CRP.
RESULTS: Receiver operating characteristic (ROC) curve analysis showed LTB4 and TXB2 to be a good discriminator between patients with chest pain of cardiac and non cardiac in origin. The area under the curve was found to be 0.988 and 0.925 for LTB4 and TXB2, respectively when compared with hs-CRP. The sensitivity and specificity of LTB4 and TXB2 were found to be 90, 85% and 95, 90%, respectively.
CONCLUSION: The measurement of LTB4 and TXB2 levels may therefore be useful to distinguish the chest pain leading to MI from that of non cardiac in origin and for the management of the disease.
Copyright © 2013 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23809385      PMCID: PMC3861261          DOI: 10.1016/j.ihj.2013.04.012

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  20 in total

1.  Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study.

Authors:  David M Iovannisci; Edward J Lammer; Lori Steiner; Suzanne Cheng; Larry T Mahoney; Patricia H Davis; Ronald M Lauer; Trudy L Burns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

2.  Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population.

Authors:  Alexander K Tsai; Na Li; Naomi Q Hanson; Michael Y Tsai; Weihong Tang
Journal:  Atherosclerosis       Date:  2009-06-18       Impact factor: 5.162

Review 3.  Significance of myocardial eicosanoid production.

Authors:  M van Bilsen; W Engels; G J van der Vusse; R S Reneman
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

4.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 5.  C-reactive protein and other inflammatory risk markers in acute coronary syndromes.

Authors:  Gavin J Blake; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

6.  Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.

Authors:  Eva Sánchez-Galán; Almudena Gómez-Hernández; Cristina Vidal; José Luis Martín-Ventura; Luis Miguel Blanco-Colio; Begoña Muñoz-García; Luis Ortega; Jesús Egido; José Tuñón
Journal:  Cardiovasc Res       Date:  2008-10-13       Impact factor: 10.787

7.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.

Authors:  Anna Helgadottir; Andrei Manolescu; Gudmar Thorleifsson; Solveig Gretarsdottir; Helga Jonsdottir; Unnur Thorsteinsdottir; Nilesh J Samani; Gudmundur Gudmundsson; Struan F A Grant; Gudmundur Thorgeirsson; Sigurlaug Sveinbjornsdottir; Einar M Valdimarsson; Stefan E Matthiasson; Halldor Johannsson; Olof Gudmundsdottir; Mark E Gurney; Jesus Sainz; Margret Thorhallsdottir; Margret Andresdottir; Michael L Frigge; Eric J Topol; Augustine Kong; Vilmundur Gudnason; Hakon Hakonarson; Jeffrey R Gulcher; Kari Stefansson
Journal:  Nat Genet       Date:  2004-02-08       Impact factor: 38.330

8.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.

Authors:  James H Dwyer; Hooman Allayee; Kathleen M Dwyer; Jing Fan; Huiyun Wu; Rebecca Mar; Aldons J Lusis; Margarete Mehrabian
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

9.  Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia.

Authors:  Jeroen B van der Net; Jorie Versmissen; Daniëlla M Oosterveer; Joep C Defesche; Mojgan Yazdanpanah; Bradley E Aouizerat; Ewout W Steyerberg; Mary J Malloy; Clive R Pullinger; John P Kane; John J P Kastelein; Eric J G Sijbrands
Journal:  Atherosclerosis       Date:  2008-08-05       Impact factor: 5.162

10.  Serum cardiac markers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic Peptide.

Authors:  Seçil Kasap; Aymelek Gönenç; Derya Erten Sener; Ismet Hisar
Journal:  J Clin Biochem Nutr       Date:  2007-07       Impact factor: 3.114

View more
  1 in total

1.  Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.

Authors:  Soeren E Pischke; A Gustavsen; H L Orrem; K H Egge; F Courivaud; H Fontenelle; A Despont; A K Bongoni; R Rieben; T I Tønnessen; M A Nunn; H Scott; H Skulstad; A Barratt-Due; T E Mollnes
Journal:  Basic Res Cardiol       Date:  2017-03-03       Impact factor: 17.165

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.